FibroBiologics (NASDAQ:FBLG) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of FibroBiologics (NASDAQ:FBLG) in a report published on Thursday, MarketBeat reports. The firm issued a buy rating and a $12.00 target price on the stock.

FBLG has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of FibroBiologics in a research note on Wednesday, November 13th. EF Hutton Acquisition Co. I raised shares of FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th. Maxim Group began coverage on shares of FibroBiologics in a report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, D. Boral Capital restated a “buy” rating and set a $16.00 price target on shares of FibroBiologics in a research note on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Price Performance

FBLG opened at $2.22 on Thursday. The company’s 50 day simple moving average is $2.79 and its two-hundred day simple moving average is $3.87. FibroBiologics has a 1-year low of $1.08 and a 1-year high of $55.00.

Hedge Funds Weigh In On FibroBiologics

Several hedge funds and other institutional investors have recently made changes to their positions in FBLG. Saxon Interests Inc. acquired a new stake in FibroBiologics in the second quarter valued at $106,000. RMR Wealth Builders acquired a new stake in shares of FibroBiologics in the 2nd quarter valued at approximately $186,000. Bank of New York Mellon Corp acquired a new stake in FibroBiologics in the second quarter valued at $342,000. Concurrent Investment Advisors LLC acquired a new stake in shares of FibroBiologics in the second quarter valued at about $176,000. Finally, Cascade Financial Partners LLC purchased a new stake in shares of FibroBiologics during the 2nd quarter worth approximately $1,572,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.